| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/FMC-2017-0080 |
| P698 | PubMed publication ID | 29172693 |
| P50 | author | Raúl Beltrán-Debón | Q42175504 |
| Santiago Garcia-Vallvé | Q43371030 | ||
| Miquel Mulero | Q80031984 | ||
| P2093 | author name string | Cristina Valls | |
| Gerard Pujadas | |||
| Adrià Cereto-Massagué | |||
| Aleix Gimeno | |||
| María José Ojeda-Montes | |||
| Andrea Ardid-Ruiz | |||
| Sarah Tomás-Hernández | |||
| P2860 | cites work | 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors | Q27644379 |
| Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation | Q27649728 | ||
| Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554 | Q27670819 | ||
| Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure | Q27720944 | ||
| A Review of Natural Stimulant and Non-stimulant Thermogenic Agents | Q28076560 | ||
| Ephedra in perspective--a current review | Q28201511 | ||
| Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family | Q28203913 | ||
| Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays | Q28483681 | ||
| Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts | Q28483936 | ||
| The Principles of Ligand Specificity on beta-2-adrenergic receptor | Q28822521 | ||
| Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010 | Q29616640 | ||
| Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. | Q33368655 | ||
| An overview on antidiabetic medicinal plants having insulin mimetic property | Q34338134 | ||
| Multi-ingredient, caffeine-containing dietary supplements: history, safety, and efficacy | Q35281767 | ||
| Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties | Q37720797 | ||
| Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects | Q38019603 | ||
| Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. | Q38122004 | ||
| DPP-IV inhibitors: Beyond glycaemic control? | Q38168002 | ||
| Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. | Q38188386 | ||
| DPP-4 inhibitors: a patent review (2012 - 2014). | Q38284522 | ||
| An overview of recent dipeptidyl peptidase-IV inhibitors: linking their structure and physico-chemical properties with sar, pharmacokinetics and toxicity | Q38531506 | ||
| Chemical composition of various Ephedra species | Q41292416 | ||
| The good, the bad and the dubious: VHELIBS, a validation helper for ligands and binding sites | Q42538022 | ||
| Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes | Q42821880 | ||
| Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8). | Q43035089 | ||
| Pancreatic Islet Regeneration by Ephedrine in Mice with Streptozotocin-induced Diabetes | Q43853447 | ||
| 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties | Q44474559 | ||
| Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. | Q44919467 | ||
| (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q45212807 | ||
| The history of Ephedra (ma-huang) | Q47317316 | ||
| Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. | Q47363647 | ||
| Soma of the Rigveda and an attempt to identify it. | Q47371589 | ||
| Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors | Q50997819 | ||
| P433 | issue | 18 | |
| P921 | main subject | (−)-ephedrine | Q219626 |
| P304 | page(s) | 2129-2146 | |
| P577 | publication date | 2017-11-27 | |
| P1433 | published in | Future Medicinal Chemistry | Q19280078 |
| P1476 | title | Ephedrine as a lead compound for the development of new DPP-IV inhibitors | |
| P478 | volume | 9 |
| Q90291678 | The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo | cites work | P2860 |
Search more.